A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
Withdrawn
- Conditions
- Chronic Migraine, Headache
- Interventions
- Biological: OnabotulinumtoxinA
- Registration Number
- NCT01749423
- Lead Sponsor
- Allergan
- Brief Summary
This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- History of chronic migraines
- 15 or more headache days over a 30 day period
- A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between 155 and 195 units
Read More
Exclusion Criteria
- Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description All participants OnabotulinumtoxinA Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
- Primary Outcome Measures
Name Time Method Number of Headache Days Up to 56 Weeks
- Secondary Outcome Measures
Name Time Method